In addition, a phase II trial of first-line single-agent pembrolizumab in NSCLC patients with PD-L1 expression <50% (including ≃30% of PD-L1 negative patients) showed a median DoR of 14.5 months with the upper CI of 24.9 months.36 The gene discussed is CD274; the disease is non-small cell lung carcinoma.